I'm not betting against Healixa. Have you watche
Post# of 30066
(Total Views: 385)
Posted On: 07/03/2021 4:16:46 PM
I'm not betting against Healixa.
Have you watched the past couple of presentations?
They are looking to disrupt the industry and just might be able to make a dent. If they do, BP or Big Healthcare will take notice.
Will MANF be coming back to AMBS?
So unclear, and how TOMDF be involved with MANF?
I can understand Amarantus getting new life via money coming in from both Investment ownership & royalties.
With the Alz drug being approved they will be more studies needed and that falls right in line with LymPro.
"With this asset now fully in our portfolio, and with the expected cash flow from our COVID-19 testing business, we believe we can continue to increase the value of LymPro as we bring it to market through our emerging U.S. and international sales channels. Additionally, because we are seeing a number of complications after recovery from COVID-19, we believe it is prudent to begin monitoring patients for early warning signs of disease, including Alzheimer’s and cancer. If early pathology emerges, it will potentially be more treatable than if found later in the course of disease.”
https://www.globenewswire.com/news-release/20...antus.html
LymPro Alzheimer’s blood test, that has shown to extremely strong correlation data (p=0.000002) with amyloid beta PET imaging SUVR scores in preliminary studies performed by our partners at Leipzig University in Germany under the direction of Dr. Thomas Arendt.
https://investor.todosmedical.com/news-events...-corporate
And this...
"As the Company engages with the investor community and NASDAQ as part of a potential listing process, it is important that we crystalize our corporate profile and begin to prioritize our resources towards the areas that will create long-term value for shareholders. For this reason, we are moving in the direction of packaging Tollovir, TolloTest, and Tollovid, three extremely exciting programs that Todos Medical has incubated as part of its push into COVID-19 at the height of the pandemic, into a separate unit of programs that will be ultimately be self-financed, spun-off, partnered and/or sold in order to create maximum shareholder return on the investment made as they make their way through their development and commercialization cycle. "
The rest of 2021 will tell a story for both TOMDF & AMBS.
My bet is that AMBS will have an epic run once TODOS begins pivoting from COVID-19 to DX testing.
And once Todos is NASDAQ listed and no share structure change in Amarantus that will be a massive benefit and right up what Amarantus is, a Holding Company.
I look forward to hearing what update Healixa & Amarantus could give.
There's a massive penalty if EMOR/ Healixa doesn't follow through.
And with the new CEO knowing the assets that puts ELTOPRAZINE back in play.
Which is great considering what's happened with Avant DX lately!
Have you watched the past couple of presentations?
They are looking to disrupt the industry and just might be able to make a dent. If they do, BP or Big Healthcare will take notice.
Will MANF be coming back to AMBS?
So unclear, and how TOMDF be involved with MANF?
I can understand Amarantus getting new life via money coming in from both Investment ownership & royalties.
With the Alz drug being approved they will be more studies needed and that falls right in line with LymPro.
"With this asset now fully in our portfolio, and with the expected cash flow from our COVID-19 testing business, we believe we can continue to increase the value of LymPro as we bring it to market through our emerging U.S. and international sales channels. Additionally, because we are seeing a number of complications after recovery from COVID-19, we believe it is prudent to begin monitoring patients for early warning signs of disease, including Alzheimer’s and cancer. If early pathology emerges, it will potentially be more treatable than if found later in the course of disease.”
https://www.globenewswire.com/news-release/20...antus.html
LymPro Alzheimer’s blood test, that has shown to extremely strong correlation data (p=0.000002) with amyloid beta PET imaging SUVR scores in preliminary studies performed by our partners at Leipzig University in Germany under the direction of Dr. Thomas Arendt.
https://investor.todosmedical.com/news-events...-corporate
And this...
"As the Company engages with the investor community and NASDAQ as part of a potential listing process, it is important that we crystalize our corporate profile and begin to prioritize our resources towards the areas that will create long-term value for shareholders. For this reason, we are moving in the direction of packaging Tollovir, TolloTest, and Tollovid, three extremely exciting programs that Todos Medical has incubated as part of its push into COVID-19 at the height of the pandemic, into a separate unit of programs that will be ultimately be self-financed, spun-off, partnered and/or sold in order to create maximum shareholder return on the investment made as they make their way through their development and commercialization cycle. "
The rest of 2021 will tell a story for both TOMDF & AMBS.
My bet is that AMBS will have an epic run once TODOS begins pivoting from COVID-19 to DX testing.
And once Todos is NASDAQ listed and no share structure change in Amarantus that will be a massive benefit and right up what Amarantus is, a Holding Company.
I look forward to hearing what update Healixa & Amarantus could give.
There's a massive penalty if EMOR/ Healixa doesn't follow through.
And with the new CEO knowing the assets that puts ELTOPRAZINE back in play.
Which is great considering what's happened with Avant DX lately!
(0)
(0)